Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 10, 2006, Pages

  Siegfried, Nandi ^a   van Deventer, Pieta JU ^b   Mahomed, Fazleh Ahmed ^c   Rutherford, George W ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Global Health Sciences ^*  (South Africa)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 33745046132     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004535.pub2     Document Type: Review

References (36)

1. French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D on behalf of the OzCombo 2 investigators. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clinical Trials 2002;3:177-185.
2. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. The Lancet 2004;363:1253-63. [PM#15094269]
3. F Garcia, M Plana, M Arnedo, GM Ortiz, JM Miro, L Lopalco, Lori F, Pumarola T, T Gallart, JM, Gatell. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003;17(43-51). [EM(FEB) #37]
4. C Katlama, B Clotet, A Plettenberg, J Jost, K Arasteh, E Bernasconi, V Jeantils, A Cutrell, A Stone, M Ait-Khaled, S Purdon on behalf of the CNA3002 European Study Team. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind trial. AIDS 2000;14:781-9.
5. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Khiri H, Halfon P. Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. HIV Medicine 2001;2:189-94.
6. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liegeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngole E, Delaporte E. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label muticentre trial. The Lancet 2004;364:29-34. [MEDLINE: PM#15234853]
7. E Negredo, L Cruz, R Paredes, L Ruiz, CR Fumaz, A Bonjoch, S Gel, A Tuldra, M Balague, S Johnston, A Arno, A Jou, C Tural, G Sirera, J Romeu, B Clotet. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases. 2002; Vol. 34:504-10. [EM(FEB)#63]
8. JM Raboud, M Harris, S Rae, JSG Montaner. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Medicine 2002;3:118-24. [EM(FEB)#59]
9. L Ruiz, G Carcelain, J Martinez-Picado, S Frost, S Marfil, R Pareded, J Romeu, E Ferrer, K Morales-Lopetegi, B Autran, B Clotet. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F19-27. [EM(FEB)#99]
10. JP Sabo, MJ Lamson, G Leitz, C Yong, TR MacGregor. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmaScience (http://www.aapspharmsci.org) 2002;2. [EM(FEB) #48]
11. Y Yazdanpanah, D Sissoko, M Egger, Y Mouton, M Zwahlen, G Chene. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ 2004;328:249-FIND THE ACTUAL PAGES. [MEDLINE: PM#14742351]
12. GJ Yuen, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, Hoelscher DD. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrobial agents and chemotherapy 2004;48:176-82. [CCTR#1]
13. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. The Journal of Infectious Diseases 2005;191:825-9.
14. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
15. British HIV Association (BHIVA) writing committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. London: British HIV Association, 2003.
16. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL. 1993 Revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The Morbidity and Mortality Weekly Report December 18, 1992;41((RR-17)).
17. Collaboration of HIV Cohorts. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. Journal of Infectious Diseases 2004;190:675-87.
18. http://www.cptech.org/ip/health/cipla/. Consumer Project on Technology.
19. Panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services. Guidelines for the use of antiretrovirals agents in HIV-infected adults and adolescents. Washington: U.S. Department of Health and Human Services, 2005.
20. N Freemantle, M Calvert, J Wood, J Eastaugh, C Griffin. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003;289(2554-9).
21. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288(2):181-8.
22. Grimwood A, Maartens G, Hussey G, Fransman D, Bamford L. HIV/AIDS and the family. First Edition. Cape Town: Hansa ReproPrint, 1998.
23. DV Havlir, SM Hammer. Patents versus patients? Antiretroviral therapy in India. NEJM 2005;353:749-51.
24. AM Hill. A meta-analysis of the effects of HIV-1 RNA methodology on estimates of HIV-1 RNA undetectability in trials of HAART. Conf Retrovriuses Opportunistic Infect. 1999; Vol. 6.
25. Ministerio da Saude, Secretaria de Vigilância em Saúde Programa Nacional de DST e Aids. Recommendations for anti-retroviral treatment of adults and adolescents with HIV infection [Recomendaçõ es para Terapia Anti-Retroviral em Adultos e Adolescentes Infectados pelo HIV]. Brasilia 2004.
26. Southern African HIV Clinicians Society. Guidelines for antiretroviral therapy in adults. Southern African Journal of HIV Medicine 2000;1(1):22-27.
27. Southern African HIV clinicians Society. Guidelines Antiretroviral Therapy in Adults. Southern African Journal of HIV Medicine 2005;March:18-31.
28. Schulz KI, Chalmers I, Hayes RJ, DG Altman. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
29. Susman E. HIV patients carry mutated drug-resistant strains. The Lancet 2002;359:49.
30. JOINT UNAIDS/WHO PRESS STATEMENT [Meeting with CIPLA]. http://www.unaids.org/whatsnew/press/eng/pressarc01/Cipla_220301.html 22 March 2001.
31. F Van Leth, JMA Lange. Correspondence: use of composite end point to measure clinical events. JAMA 2003;290:1456-7.
32. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-95.
33. Weller IV, Williams IG. ABC of AIDS. Antiretroviral drugs. BMJ 2001;322(7299):1410-2.
34. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: a public health approach (2003 revision). Geneva: World Health Organization, 2004.
35. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: World Health Organization, 2004.
36. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl, MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schecter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel. JAMA 2002;288(2):222-235.